The data evaluated Medtronic’s Smart MDI system, which combines the InPen with the Simplera continuous glucose monitor (CGM). Data showed how the system, designed for people with diabetes using multiple daily injections (MDI) when used as intended, helps users get closer to the internationally recommended 70% time in range (TIR) target.

Medtronic shared data today at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Amsterdam. The medtech giant says it aims for its system to minimize the frequency of glucose highs for those on MDI.

According to a news release, less than 30% of people with diabetes using CGM achieve the glycemic target of HbA1c < 7%. Studies show that MDI, alongside regular blood glucose monitoring, achieves a TIR of only 45%. MDI accompanied by intermittently scanned CGM brings TIR to 51%, still well short of the 70% target.